InsiderTrades.com logo

PMN Insider Trading

Insider Ownership Percentage: 3.80%
Insider Buying (Last 12 Months): $29,433.75
Insider Selling (Last 12 Months): $0.00

Promis Neurosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Promis Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Promis Neurosciences Share Price & Price History

Current Price: $7.63
Price Change: ▲ Price Increase of +0.27 (3.67%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for PMN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Promis Neurosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/3/2025Max A MilburyInsiderBuy1,215$12.25$14,883.751,815View SEC Filing Icon  
2/10/2025Neil CashmanInsiderBuy600$24.25$14,550.00664View SEC Filing Icon  
9/23/2024Madge K ShafmasterDirectorBuy2,800$32.00$89,600.005,533View SEC Filing Icon  
9/20/2024Madge K ShafmasterDirectorBuy2,400$31.25$75,000.002,733View SEC Filing Icon  
8/14/2024Patrick D KirwinDirectorBuy400$31.25$12,500.002,519View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Promis Neurosciences (NASDAQ:PMN)

50.13% of Promis Neurosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PMN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Promis Neurosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2025Armistice Capital LLC2,974,518$1.26M0.0%+39.1%5.528%Search for SEC Filing on Google Icon
11/17/2025Citadel Advisors LLC170,079$72K0.0%+168.1%0.316%Search for SEC Filing on Google Icon
11/17/2025Ally Bridge Group NY LLC6,233,497$2.65M1.6%+367.1%11.584%Search for SEC Filing on Google Icon
8/14/2025Armistice Capital LLC2,137,896$1.03M0.0%-8.4%6.540%Search for SEC Filing on Google Icon
5/16/2025Allostery Investments LP233,703$0.17M0.2%+19.8%0.715%Search for SEC Filing on Google Icon
5/16/2025Ally Bridge Group NY LLC1,484,699$1.03M0.9%-6.8%4.542%Search for SEC Filing on Google Icon
5/15/2025Armistice Capital LLC2,334,826$1.62M0.0%-7.0%7.143%Search for SEC Filing on Google Icon
2/17/2025Allostery Investments LP195,111$0.19M0.2%N/A0.597%Search for SEC Filing on Google Icon
2/14/2025Heights Capital Management Inc.160,207$0.15M0.1%-58.6%0.490%Search for SEC Filing on Google Icon
11/15/2024Sphera Funds Management LTD.1,929,297$2.41M0.4%+6.3%6.455%Search for SEC Filing on Google Icon
11/14/2024Ally Bridge Group NY LLC1,592,605$1.99M1.1%+50.3%5.328%Search for SEC Filing on Google Icon
11/13/2024Great Point Partners LLC2,790,698$3.49M1.0%N/A9.337%Search for SEC Filing on Google Icon
2/7/2024Ieq Capital LLC30,799$35K0.0%-21.4%0.163%Search for SEC Filing on Google Icon
11/15/2023Affinity Asset Advisors LLC265,958$0.53M0.1%N/A3.100%Search for SEC Filing on Google Icon
11/15/2022Northeast Financial Consultants Inc100,000$0.61M0.0%N/A1.166%Search for SEC Filing on Google Icon
11/4/2022Ieq Capital LLC39,191$0.24M0.0%N/A0.457%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Promis Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More on Promis Neurosciences

Today's Range

Now: $7.63
Low: $7.44
High: $7.75

50 Day Range

MA: $10.28
Low: $6.54
High: $14.24

52 Week Range

Now: $7.63
Low: $6.27
High: $39.75

Volume

18,742 shs

Average Volume

38,932 shs

Market Capitalization

$16.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Promis Neurosciences?

Promis Neurosciences' top insider investors include:
  1. Madge K Shafmaster (Director)
  2. Patrick D Kirwin (Director)
  3. Max A Milbury (Insider)
  4. Neil Cashman (Insider)
Learn More about top insider investors at Promis Neurosciences.

Who are the major institutional investors of Promis Neurosciences?

Promis Neurosciences' top institutional investors include:
  1. Ally Bridge Group NY LLC — 11.58%
  2. Armistice Capital LLC — 5.53%
  3. Citadel Advisors LLC — 0.32%
Learn More about top institutional investors of Promis Neurosciences stock.

Which major investors are buying Promis Neurosciences stock?

During the last quarter, PMN stock was purchased by institutional investors including:
  1. Ally Bridge Group NY LLC
  2. Armistice Capital LLC
  3. Citadel Advisors LLC
In the last year, these company insiders have bought Promis Neurosciences stock:
  1. Madge K Shafmaster (Director)
  2. Patrick D Kirwin (Director)
  3. Max A Milbury (Insider)
  4. Neil Cashman (Insider)
Learn More investors buying Promis Neurosciences stock.